Status:
UNKNOWN
Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the present study is to evaluate the long-term observation, in terms of overall survival, of adult Ph+ ALL patients treated frontline with the sequential administration of das...
Detailed Description
Since the treatment after dasatinib and blinatumomab is not uniform and highly dependent on medical decisions, the primary aim of this ancillary trial is to evaluate the long-term follow-up of patient...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Study LAL2217 Informed Consent signature.
- Patients enrolled in the GIMEMA LAL2116 protocol and who have completed the 12 months follow-up
Exclusion
Key Trial Info
Start Date :
May 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03318770
Start Date
May 10 2019
End Date
May 1 2024
Last Update
October 12 2022
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
Bari, Italy
2
Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia
Bergamo, Italy
3
Asst Degli Spedali Civili Di Brescia - Uo Ematologia
Brescia, Italy
4
Ctc U.O Di Ematologia Con Trapianto Di Midollo Osseo - Catania
Catania, Italy